<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826150</url>
  </required_header>
  <id_info>
    <org_study_id>BC-08-01</org_study_id>
    <nct_id>NCT00826150</nct_id>
  </id_info>
  <brief_title>Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer</brief_title>
  <official_title>Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anchiano Therapeutics Israel Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anchiano Therapeutics Israel Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and
      preliminary efficacy of DTA-H19 administered intraperitoneally (IP) in subjects with advanced
      stage ovarian cancer, or primary peritoneal carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a, open label, dose escalation, repeat dose study in 11 subjects with
      recurrent, platinum resistant advanced stage ovarian cancer or primary peritoneal carcinoma
      designed to determine the tolerability, safety, quality of life, PK, and preliminary efficacy
      of DTA-H19 administered intraperitoneally(IP).

      Primary Objective: The primary objectives of this study are:

        -  To determine the maximum tolerated dose (MTD) of IP DTA-H19; and,

        -  To identify any dose limiting toxicities (DLTs).

      Secondary Objectives: Secondary objectives of this study are:

        -  To determine quality of life of subjects with advanced ovarian cancer, primary
           peritoneal carcinoma treated with IP DTA-H19;

        -  To determine the the reduction in malignant ascites as measured by Ultrasound and change
           in frequency of parecenteses necessary.

        -  To determine the overall survival distribution.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose-Limiting Toxicities</measure>
    <time_frame>8 weeks</time_frame>
    <description>A dose limiting toxicity (DLT) was defined as any grade 3 or greater non-hematologic AE by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). If one subject in a cohort experienced a DLT, then three additional subjects had to be enrolled to that cohort unless a second subject in that cohort experiences a DLT. The next lower dose was to be considered the MTD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in ITT Population</measure>
    <time_frame>17.5 months</time_frame>
    <description>Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solid Tumor Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>If measurable disease was present, then the response of each marker lesion was evaluated separately and rated for response according to RECIST criteria for solid tumors.
Complete Response: Disappearance of the target lesion. Partial Response: At least a 30% decrease in the longest diameter of the target lesion.
Stable Disease: No sufficient shrinkage to qualify for partial response, or sufficient increase to qualify for progressive disease.
Progressive Disease: At least a 20% increase in the longest diameter of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic BC-819 Pharmacokinetics (PK) by Treatment - T1/2 (Hours)</measure>
    <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
    <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic BC-819 Pharmacokinetics (PK) - Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
    <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic BC-819 Pharmacokinetics (PK) by Treatment - Tmax (Hours)</measure>
    <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
    <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUClast</measure>
    <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
    <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUCinf</measure>
    <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
    <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in PP</measure>
    <time_frame>17.5 months</time_frame>
    <description>Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>BC-819</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BC-819 60, 120 and 240 mg IP administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BC-819</intervention_name>
    <description>Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
    <arm_group_label>BC-819</arm_group_label>
    <other_name>DTA-H19</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent and be at least 18 years of age.

          -  Have histopathologically documented epithelial ovarian carcinoma or primary peritoneal
             carcinoma with evidence of ascites.

          -  Have either a) platinum-refractory disease (i.e. persistent disease following
             completion of platinum-based primary chemotherapy) and have failed at least primary
             platinum-based chemotherapy; or b) platinum-resistant recurrent disease and have
             failed at least one regimen of second line chemotherapy.

          -  Be able to tolerate placement of IP catheter.

          -  Be at least 2 weeks from last treatment to allow recovery from prior toxicity but in
             the judgment of the investigator with sufficient time to ensure that the effects of
             prior treatments will not confound safety evaluations.

          -  Have a Karnofsky performance status score of ≥ 70%.

          -  Not be of child-bearing potential.

          -  Have a life expectancy of ≥ 3 months.

          -  Have serum creatinine &lt; 2.0 mg/dL, total bilirubin less than the institution's 3x
             upper limit of normal (ULN); AST and ALT &lt;= 2.5 x ULN,total albumin ≥ 2.5 g/dL, PT,
             PTT, and PT/INR within normal limits, absolute neutrophil count (ANC) &gt; 1,500 x 103
             cells/mL, platelets ≥ 100,000/mL, and hemoglobin ≥ 10 mg/dL.

          -  Have a biopsy specimen or an ascites fluid that is positive for H19 expression.

          -  Have screening procedures completed within 6-weeks before starting treatment.

          -  No significant history of cardiac disease, i.e., uncontrolled hypertension, unstable
             angina or congestive heart failure.

          -  - No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy,
             immunotherapy or any other type of therapy for treatment of cancer while on this
             protocol.

        Exclusion Criteria:

          -  Have evidence of extra abdominal disease with the exception of isolated small nodules
             (e.g., liver or pulmonary nodules) that are not causing symptoms.

          -  Have known brain metastases.

          -  Have known HIV infection.

          -  Have known active viral or bacterial infections.

          -  Have presence of any psychological, familiar, sociological, or geographical condition
             potentially hampering compliance with the study protocol or follow up schedule.

          -  Have a medical condition contraindicated for laparotomy, laparoscopy, or surgery.

          -  Have significant bowel involvement denoted by persistent grade 3 vomiting (≥6 episodes
             in 24 hrs; IV fluids, or total parenteral nutrition (TPN) indicated ≥24 hrs) after
             removal of ascites, inability to tolerate oral diet or medications, requirement for
             total parenteral nutrition, or recent (past six weeks) episode of bowel obstruction.

          -  Have a history of coagulopathy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tally Levy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Edith Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Edelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ami Fishman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eitan Rami, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ofer Lavie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronnie Shapira-Frommer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 18, 2009</study_first_submitted>
  <study_first_submitted_qc>January 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>August 22, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 13, 2019</results_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>H19 gene</keyword>
  <keyword>plasmid</keyword>
  <keyword>inodiftagene vixteplasmid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BC-819 60 mg IP</title>
          <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses/ 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="P2">
          <title>BC-819 120 mg IP</title>
          <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="P3">
          <title>BC-819 240 mg IP</title>
          <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BC-819 60 mp IP</title>
          <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="B2">
          <title>BC-819 120 mg IP</title>
          <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="B3">
          <title>BC-819 240 mg IP</title>
          <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="12"/>
                    <measurement group_id="B2" value="61.3" spread="3.1"/>
                    <measurement group_id="B3" value="54.3" spread="7.6"/>
                    <measurement group_id="B4" value="59.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose-Limiting Toxicities</title>
        <description>A dose limiting toxicity (DLT) was defined as any grade 3 or greater non-hematologic AE by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). If one subject in a cohort experienced a DLT, then three additional subjects had to be enrolled to that cohort unless a second subject in that cohort experiences a DLT. The next lower dose was to be considered the MTD.</description>
        <time_frame>8 weeks</time_frame>
        <population>Per Protocol data set (PP): 11 subjects who met the study inclusion and exclusion criteria, received at least one course of treatment of the investigational product and had a follow-up disease assessment comprised the PP set (5 subjects from the 60 mg cohort, 3 subjects from the 120 mg cohort; 3 subjects from the 240 mg cohort).</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose-Limiting Toxicities</title>
          <description>A dose limiting toxicity (DLT) was defined as any grade 3 or greater non-hematologic AE by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). If one subject in a cohort experienced a DLT, then three additional subjects had to be enrolled to that cohort unless a second subject in that cohort experiences a DLT. The next lower dose was to be considered the MTD.</description>
          <population>Per Protocol data set (PP): 11 subjects who met the study inclusion and exclusion criteria, received at least one course of treatment of the investigational product and had a follow-up disease assessment comprised the PP set (5 subjects from the 60 mg cohort, 3 subjects from the 120 mg cohort; 3 subjects from the 240 mg cohort).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in ITT Population</title>
        <description>Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.</description>
        <time_frame>17.5 months</time_frame>
        <population>Intent to Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mp IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in ITT Population</title>
          <description>Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.</description>
          <population>Intent to Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.6" upper_limit="16.7"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.2" upper_limit="8.3"/>
                    <measurement group_id="O3" value="6.5" lower_limit="1.6" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solid Tumor Response</title>
        <description>If measurable disease was present, then the response of each marker lesion was evaluated separately and rated for response according to RECIST criteria for solid tumors.
Complete Response: Disappearance of the target lesion. Partial Response: At least a 30% decrease in the longest diameter of the target lesion.
Stable Disease: No sufficient shrinkage to qualify for partial response, or sufficient increase to qualify for progressive disease.
Progressive Disease: At least a 20% increase in the longest diameter of the target lesion.</description>
        <time_frame>6 weeks</time_frame>
        <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT. 13 patients of the ITT population (n=14) were evaluated (one patient was not assessed for solid tumor response in the BC-819 60 mg IP Arm).</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Solid Tumor Response</title>
          <description>If measurable disease was present, then the response of each marker lesion was evaluated separately and rated for response according to RECIST criteria for solid tumors.
Complete Response: Disappearance of the target lesion. Partial Response: At least a 30% decrease in the longest diameter of the target lesion.
Stable Disease: No sufficient shrinkage to qualify for partial response, or sufficient increase to qualify for progressive disease.
Progressive Disease: At least a 20% increase in the longest diameter of the target lesion.</description>
          <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT. 13 patients of the ITT population (n=14) were evaluated (one patient was not assessed for solid tumor response in the BC-819 60 mg IP Arm).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - T1/2 (Hours)</title>
        <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
        <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
        <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - T1/2 (Hours)</title>
          <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
          <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.41" spread="5.24"/>
                    <measurement group_id="O2" value="21.98" spread="12.71"/>
                    <measurement group_id="O3" value="42.04" spread="58.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic BC-819 Pharmacokinetics (PK) - Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
        <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
        <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses/ 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic BC-819 Pharmacokinetics (PK) - Maximum Observed Plasma Concentration (Cmax)</title>
          <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
          <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
          <units>copies/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830000" spread="640000"/>
                    <measurement group_id="O2" value="750000" spread="1050000"/>
                    <measurement group_id="O3" value="430000" spread="340000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - Tmax (Hours)</title>
        <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
        <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
        <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses/ 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - Tmax (Hours)</title>
          <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
          <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="2.14"/>
                    <measurement group_id="O2" value="2.67" spread="1.16"/>
                    <measurement group_id="O3" value="9.33" spread="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUClast</title>
        <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
        <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
        <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses/ 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUClast</title>
          <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
          <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
          <units>copies*hr/μl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1600000" spread="1700000"/>
                    <measurement group_id="O2" value="10600000" spread="15100000"/>
                    <measurement group_id="O3" value="5300000" spread="1900000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUCinf</title>
        <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
        <time_frame>Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion</time_frame>
        <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses/ 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUCinf</title>
          <description>Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.</description>
          <population>Intent To Treat (ITT) data set: subjects who participated in the study were included in the safety and in the ITT analysis. All 14 subjects who participated in the study were included in the ITT.</population>
          <units>copies*hr/μl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1900000" spread="1900000"/>
                    <measurement group_id="O2" value="16200000" spread="24400000"/>
                    <measurement group_id="O3" value="12500000" spread="9800000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in PP</title>
        <description>Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.</description>
        <time_frame>17.5 months</time_frame>
        <population>Per Protocol data set (PP): 11 subjects who met the study inclusion and exclusion criteria, received at least one course of treatment of the investigational product and had a follow-up disease assessment comprised the PP set (5 subjects from the 60 mg cohort, 3 subjects from the 120 mg cohort; 3 subjects from the 240 mg cohort).</population>
        <group_list>
          <group group_id="O1">
            <title>BC-819 60 mg IP</title>
            <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses/ 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O2">
            <title>BC-819 120 mg IP</title>
            <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
          <group group_id="O3">
            <title>BC-819 240 mg IP</title>
            <description>240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in PP</title>
          <description>Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.</description>
          <population>Per Protocol data set (PP): 11 subjects who met the study inclusion and exclusion criteria, received at least one course of treatment of the investigational product and had a follow-up disease assessment comprised the PP set (5 subjects from the 60 mg cohort, 3 subjects from the 120 mg cohort; 3 subjects from the 240 mg cohort).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.2" upper_limit="8.3"/>
                    <measurement group_id="O3" value="6.5" lower_limit="4.5" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed over a 16 week period, starting with each participant’s first treatment with IP.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BC-819 60 mg IP</title>
          <description>60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="E2">
          <title>BC-819 120 mg IP</title>
          <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
        <group group_id="E3">
          <title>BC-819 240 mg IP</title>
          <description>120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain and dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Clinical deterioration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection of port</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness and shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>All other Gastrointestinal disorders excluding constipation, diarrhea, Dyspepsia, and vomiting.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>All other general disorders and administration site conditions excluding Asthenia and general physical health deterioration.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>All other Injury, poisoning and procedural complications excluding fall</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>All other investigations excluding those listed in this table.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hedache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>All other renal and urinary disorders excluding urinary tract infection.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Clinical</name_or_title>
      <organization>BioCancell Ltd.</organization>
      <phone>+97225486553</phone>
      <email>monique.ben-am@biocancell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

